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Abstract
BACKGROUND: In the most patients with differentiated thyroid carcinoma (DTC), recurrent disease occurs in the neck region, 
but the usefulness of neck ultrasound (US) in its diagnosis is not clear. The aim of this study was to evaluate the significance 
of US in the detection of neck recurrence in low-risk DTC patients at first follow-up visits.
MATERIAL AND METHODS: A total of 32 patients, who had a history of DTC and radioiodine therapy after thyroidectomy 
with low doses of iodine 131 (3.7 GBq), were enrolled in this study. About 6 months after first ablation, the patients underwent 
clinical examination, iodine 131 scanning, measurement of thyroglobulin (Tg) after T4 withdrawal, thyroid-stimulating hormone 
measurement, TgAb measurement, and neck sonography with US. 
RESULTS: Recurrence of thyroid cancer was suspected in the neck region in 17 patients (53.1%) of the study cohort. There were 
six groups based on the results of posttreatment serum Tg levels, 131I whole body scan (131I WBS), and US in the detection 
of DTC neck recurrences. Fifteen patients had negative results of three modalities (group 1); seven patients had US evidence 
of neck lesions but negative 131I WBS and serum Tg results(group 2); three patients had positive results of 131I WBS but 
negative US and serum Tg results (group 3); four patients had positive results of serum Tg results but negative US and 131I 
WBS results (group 4); two patients lacked 131I WBS evidence of neck lesions, but US and serum Tg suggested the diagnosis 
of neck recurrence (group 5), and one subject had evidence of neck recurrence in three modalities (group 6).
CONCLUSION: These findings may imply that neck sonography together with determination of serum Tg levels and 131I WBS 
after thyroid-stimulating hormone therapy should be considered the diagnostic modality of choice for postoperative surveil-
lance, even in low-risk DTC patients.
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Background
Differentiated thyroid carcinoma (DTC) is distinguished by 
an indolent growth rate with low morbidity and mortality [1]; how-
ever, cancer recurrence increases its mortality rate [2] and 8% of 
patients with local recurrence will ultimately die from cancer [3].
In patients with low-risk DTC, follow-up is carried out with 131I 
whole body scan (131I WBS) and serum thyroglobulin (Tg) measu-
rements [4, 5]; however, 131I WBS has insufficient sensitivity for 
this purpose [6–9]. Serum Tg levels in these patients can also have 
limited sensitivity [10].
In the most patients with DTC, recurrent disease occurs in the 
neck region, but the usefulness of neck ultrasound (US) in its dia-
gnosis is not clear [11]. Some authors have proposed its routine 
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use because it can overcome the limitations of serum Tg levels and 
131I WBS in the detection of locoregional disease [6–8, 12–17].
The aim of this study was to assess the significance of US in the 
diagnosis of recurrent DTC in the neck region and the contribution 
of US in the early diagnosis of low-risk DTC patients.
Materials and methods
Participants and study design
In this retrospective study, we recruited 32 patients over a pe-
riod of 2 years, from August 2009 to May 2011. All patients had 
a history of DTC and radioiodine therapy after thyroidectomy with 
low doses of iodine 131 (3.7 GBq). No patient had extra-thyroid 
uptake on the pretreatment 131I WBS scan (diagnostic scan). All 
patients had undetectable serum anti-Tg antibody (TgAb) levels. 
The patients underwent clinical examination; 131I WBS; measure-
ments of Tg, TgAb, and thyroid-stimulating hormone (TSH) after 
stopping levothyroxine for 1 month and liothyronine for 2 weeks; 
and neck sonography. The interval between the first ablation therapy 
and the visits was about 6 months in all patients. Patients were cau-
tiously questioned about any exposure to exogenous iodine before 
scanning, and all patients were informed to avoid drugs containing 
iodine during the preparation period for the diagnostic scan. Patient 
clothing was changed before scanning to prevent contamination. 
At the time of the 131I WBS, all patients had a serum TSH level 
above 30 mIU/L. 
Clinical examination was the palpation of the neck area for the 
diagnosis of lymph nodes or masses located in the neck, which 
was always performed by the same physician (MM). Initial surgi-
cal procedures included thyroid and central neck compartment 
dissection. Also, in suspicious cases, lymph node dissection 
was performed and checked histopathologically. All the included 
patients did not have any lymph node involvement. 
This study was approved by the institutional ethics committee 
of Isfahan University of Medical Sciences, and all patients gave 
written informed consent.
Detection of neck recurrence
Neck recurrence is defined as a lesion in a patient who pre­
viously considered free of residual neck tumors following surgical 
manipulation and thyroid remnant ablation [8, 18]. In our partici-
pants, diagnosis of DTC neck recurrence was based on fine­needle 
aspiration biopsy (FNAB). Patients with normal sonographic 
findings but positive Tg results or positive WBS results or both 
were considered to have cervical recurrence. Absence of disease 
was described as negative Tg, 131I WBS, and sonographic find-
ings as well as negative Tg and 131I WBS results and negative 
findings for neoplasia by FNAB in the patients with abnormal 
sonographic findings.
Acquisition protocols
For I131 WBS scintigraphy, patients took 185 MBq 131I orally, 
and scanning was performed 48 h later. Planar images were ac-
quired by a gamma camera (Scintronix, UK) with a high-energy 
parallel hole collimator with an energy setting of 364 keV ± 10%. 
Images were interpreted by two experienced nuclear medicine 
physicians. 
Neck US examination
Sonography was carried out with a linear multifrequency 7.5– 
–10 MHz transducer. Suspected lymph node and mass lesions were 
conducted by FNA with a 23-gauge needle and a 5 or 10 mL syringe. 
The smears were prepared with hematoxylin and eosin, 
Papanicolaou, and Giemsa stains and evaluated by a cyto-
pathologist experienced in DTC.
Measurement of serum thyroglobulin
Serum Tg and anti-Tg antibody levels were measured by ra-
dioimmunoassay using commercial kits (BRAHMS Tg-plus DYNO 
test and BRAHMS anti-Tgn DYNO test, respectively). Since TSH 
was raised in all patients, Tg levels ≥ 2 µg/L were considered ab-
normal [8]. Because circulating AbTg interferes with Tg assays, we 
routinely screened all participants for serum anti-Tg antibody, using 
passive hemagglutination. Patients with positive anti-Tg antibody 
and negative Tg were excluded from this study. In addition, serum 
TSH was determined with a third-generation double antibody assay. 
Statistical analysis
Serum Tg levels before and after I-131 therapy were compared 
using the Wilcoxon signed-rank test. In addition, a Chi-square test 
was used to compare differences between categorical variables. A P 
value of 0.05 or less was considered significant. Statistical analy-
sis was performed using SPSS version 18 (SPSS Inc., Chicago, IL).
Results
A total of 32 patients (25 females and seven males) with a mean 
age of 44.81 ± 11.50 years took part in the study. All patients had 
the papillary type of DTC (PCDTC). During the initial operation, all 
patients underwent total thyroidectomy.
All patients received 3.7 GBq (100 mCi) radioiodine. The mean 
pretreatment Tg was 17.25 ± 9.95 ng/mL (range 1–45 ng/mL), 
the mean posttreatment Tg was 12.31 ± 28.30 ng/mL (range 
0.00–130 ng/mL), and the difference was not statistically significant 
(P > 0.05). 
Recurrence of thyroid cancer was suspected in the neck region 
in 17 patients (53.1%). Based on the findings of the serum Tg as-
sessment, seven patients demonstrated an increment in posttreat-
ment Tg relative to pretreatment Tg values, while the remaining 25 
patients showed a decrease in the Tg value. 
In the posttreatment 131I WBS, four patients showed increased 
activity in the neck region. The remaining 28 cases had no abnormal 
activity on 131I WBS in the posttreatment survey.
There were six groups based on the results of posttreatment 
serum Tg levels, 131I WBS, and US in the detection of DTC 
neck recurrences. Fifteen patients had negative results of three 
modalities (group 1); seven patients had US evidence of neck 
lesions but negative 131I WBS and serum Tg results (group 2); 
three patients had positive results of 131I WBS but negative US 
and serum Tg results (group 3); four patients had positive results of 
serum Tg but negative US and 131I WBS results (group 4); two 
patients lacked 131I WBS evidence of neck lesions but US and 
serum Tg suggested the diagnosis of neck recurrence (group 5), 
and one subject had evidence of neck recurrence in three modali-
ties (group 6) (Table 1).
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In total, 10 patients presented a lesion in the neck region with 
a diameter range of 5–15 mm on US examination. Recurrences were 
not palpable upon clinical exam in any patient. Ultrasound-guided 
FNAB was performed in nine of 32 patients (seven cases in group 
2 and two cases in group 5) who had US findings suspicious for 
DTC neck recurrence. FNAB was not performed in one patient in 
group 6. Cytology was indicative of malignancy in four cases in 
group 2 and one case in group 5; in four cases, this showed reac-
tive lymphadenitis. 
The all five patients were underwent repeated surgery and 
received 5.55 GBq doses of 131I. 
Discussion
The classic treatment for differentiated thyroid cancer (DTC) 
is surgical resection followed by 131I ablation [19]. However, even 
with this standard therapy, the recurrence rate of thyroid cancer 
is 20% [20]. 
Serum Tg in the absence of TgAb and stimulated by raised 
TSH is the most sensitive marker for diagnosis of tumor recur-
rence after initial therapy [21, 22]. However, some patients might 
not be distinguished by Tg measurement alone, especially those 
with local recurrences [23]. In a review including eight studies in 
low-risk patients, Tg failed to detect 9% of recurrences, all in the 
neck [24]; this issue was also observed in other studies [6, 7]. In 
our study, levels of Tg after T4 withdrawal of 2 ng/mL or greater 
were observed in seven out of 14 (50%) patients with recurrence, 
yielding questionable sensitivity but similar to values reported in 
previous studies [8, 25].
Diagnostic iodine scan has inadequate sensitivity, especially for 
detection of cervical metastases, and is therefore of limited utility in 
this situation [8, 12, 26]. In our series, 131I WBS showed four out 
of 14 (28.6%) patients with neck recurrence. 
In our low-risk series, neck recurrences occurred in six out of 32 
(18.7%) patients, which was similar to previous results [8]. These 
data support the need for careful surveillance of the neck region, 
even in low-risk patients.
Moreover, an important finding in this study is that US pro-
vides early diagnosis of suspected recurrences that were not 
detected by serum Tg and 131I WBS. Serum Tg and 131I WBS 
results were negative in four out of 32 (12.5%) of the patients with 
neck recurrences that were detected by US examination.
Several explanations may clarify these findings. First, the small 
size of some tumor recurrences may reduce 131I uptake and Tg 
production and release as seen in our study; the maximum tumor 
size in our study was 15 mm. Due to their small size and/or their 
deep location, no patient with neck recurrence was suspected on 
clinical examination. 
Second, the absence of tumor cell differentiation has been 
seen in patients with DTC local recurrences [27, 28]. Third, al-
though patients with positive anti-Tg antibodies were not included 
in this investigation, slight interference from low levels of anti-Tg 
antibodies cannot be excluded [8]. 
The follow-up approach in DTC recurrence in regional lymph 
nodes is not clearly defined [29, 30]. After surgical resection of thy-
roid cancer, it is advised to have neck US after 6 and 12 months and 
every 3–5 years thereafter [29, 31]. 
The US findings are useful; however, they do not provide suf-
ficient information to ascertain the diagnosis of thyroid cancer 
recurrence in the neck region [30, 32]. Some echogenic signs may 
help detect a malignant process in the neck; however, morphologic 
features must be confirmed by cytopathological survey [30, 32]. 
For that reason, ultrasound-guided FNAB should be carried out in 
any suspicious situation of cancer recurrence.
Seo et al. compared the diagnostic values of US, contrast-en-
hanced computed tomography (CT), and F-FDG positron emission 
tomography (PET)/CT for detecting recurrent DTC in the neck in 20 
patients [33]. The sensitivity, specificity, and accuracy were 69.2%, 
89.7%, and 80.0% for ultrasound; 63.5%, 94.8%, and 80.0% for 
CT; and 53.8%, 79.3%, and 67.3% for PET/CT, respectively [33]. 
This study demonstrated that US may detect neck recurrences in 
low-risk DTC patients with an otherwise negative follow-up. 
On evaluating these data, we support the idea that use of US 
for follow-up of DTC is essential. However, US examination did not 
show neck recurrences in three patients with positive 131I WBS and 
in four patients with positive serum Tg levels. In addition, the other 
limitation of US examination is that the accuracy of this modality 
is operator dependent. Therefore, our data indicate that the com-
bination of the three diagnostic modalities (measurement of serum 
Tg level, US, and 131I WBS) gives excellent follow-up results and 
provides optimal treatment.
It should be stated that our study had some limitations, such 
as its small sample size and that we could not follow up over a pro-
longed period of time. In addition, the PET facility was not available 
to obtain precise statistical parameters. However, further evidence 
is needed to confirm our preliminary results.
Conclusion
Our findings suggest that neck sonography together with the 
determination of serum Tg levels and 131I WBS after TSH stimula-
tion should be considered the diagnostic modality of choice for 
postoperative surveillance, even in low-risk DTC patients.
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